Polyrizon Ltd. (PLRZ)
NCM · Healthcare · Biotechnology
$11.70
+3.91%
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
Market Cap
$24.4M
Shares Outstanding
2.1M
Exchange
NCM
Currency
USD
About Polyrizon Ltd.
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company uses its proprietary technology to develop its products comprising Capture and Contain, a barrier against a range of allergen particulates and viruses; and Trap and Target for nasal delivery of active pharmaceutical ingredients. It also develops PL-14, a nasal allergies blocker; and PL-16 for influenza blockers. Polyrizon Ltd. was incorporated in 2005 is headquartered in Ra'anana, Israel.
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -895K | -635K | -1.3M | -5.8M |
| Net Income | -779K | -600K | -1.5M | -3.3M |
| Diluted EPS | $-294.35 | $-239.27 | $-805.20 | $nan |